{"id":"NCT04036253","sponsor":"Bio Sidus SA","briefTitle":"Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease","officialTitle":"A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-28","primaryCompletion":"2021-06-15","completion":"2021-08-31","firstPosted":"2019-07-29","resultsPosted":"2025-03-20","lastUpdate":"2025-03-20"},"enrollment":43,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia of Chronic Kidney Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Erythropoietin alfa","otherNames":[]}],"arms":[{"label":"Eprex/Erypo","type":"ACTIVE_COMPARATOR"},{"label":"Hemax PFS","type":"EXPERIMENTAL"}],"summary":"Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate efficacy and safety of Hemax PFS® (PFS: prefilled syringes) vs the innovator erythropoietin alfa product (Eprex®).","primaryOutcome":{"measure":"Efficacy Evaluation Through Change in Hemoglobin Levels","timeFrame":"12 weeks of treatment","effectByArm":[{"arm":"Eprex/Erypo","deltaMin":9.56,"sd":0.6},{"arm":"Hemax PFS","deltaMin":9.44,"sd":0.81}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":11,"countries":["Argentina","Paraguay"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Increased blood pressure","Lower limb edema","Increased lipids","Hypoglycemia","Acute bronchitis"]}}